- Home
- ALLE vs BBIO Comparison
ALLE vs BBIO Comparison
Compare ALLE & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALLE | BBIO |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9B | 15.3B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | ALLE | BBIO |
|---|---|---|
| Price | $167.34 | $77.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 21 |
| Target Price | ★ $170.33 | $78.81 |
| AVG Volume (30 Days) | 878.3K | ★ 2.9M |
| Earning Date | 02-18-2026 | 02-19-2026 |
| Dividend Yield | ★ 1.23% | N/A |
| EPS Growth | ★ 13.70 | N/A |
| EPS | ★ 7.39 | N/A |
| Revenue | ★ $3,979,700,000.00 | $353,780,000.00 |
| Revenue This Year | $10.07 | $129.14 |
| Revenue Next Year | $6.33 | $78.96 |
| P/E Ratio | $22.40 | ★ N/A |
| Revenue Growth | 6.87 | ★ 62.46 |
| 52 Week Low | $116.57 | $28.33 |
| 52 Week High | $180.68 | $81.33 |
Technical Indicators
Market Signals| Indicator | ALLE | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 57.95 | 54.90 |
| Support Level | $162.42 | $76.25 |
| Resistance Level | $168.58 | $80.00 |
| Average True Range (ATR) | 3.14 | 2.73 |
| MACD | 0.12 | -0.19 |
| Stochastic Oscillator | 72.53 | 56.25 |
Price Performance
Historical ComparisonAbout ALLE Allegion plc
Allegion is a global security products company with a portfolio of leading brands such as Schlage, Von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2024, Allegion generated over 75% of sales in the United States. The company primarily competes with Sweden-based Assa Abloy, Switzerland-based Dormakaba, and US-based Fortune Brands Innovations.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.